Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Chinese get GBM too. Humanity should be introduced to DCVAX soon. Let’s see that topline data!! Patients need this.
Something’s up. Trading between .3285 and .285 on 1.6 million shares. There’s a battle going on here. At some point, one side or the other will be overwhelmed.
Maybe in 5-10 years. More likely $20-$25 in 3-5 years.
Great! More shares to cover.
The risk to reward here is unprecedented. I expect an AMRN like response to topline and a quick jump up to $7, with a retreat to $4-$5. From there, a slow march up to a buyout of between $15-$20 within 3 years.
Don’t get rid of all of your AMRN. They’re probably looking at a potential $40-$50 buyout in the next couple of years. Not the same potential as NWBO, but it carries less risk as well.
We’re back up over .29. Linda Liau must have booked a flight to Chicago.
If Linda Powers ends up a billionaire, it will be because she risked a lot of her own personal capital and life into the science behind DCVAX. Until we see P3 unblinded data, it remains potential.
I made the same wrong assumption earlier this year and was corrected at that time. BlackRock bought Sequoia capital group which funded the private buyout. It did not buy Cognate.
If he doesn’t concede on amazing data, he’ll be stuck wearing that helmet if he ends up with GBM.
If the market makers are using algorithms that still predict failure probability of NWBO at 50%, they could match that to their short positions. Significantly positive topline data could initiate a short cover of between 100-250 million shares. Another 100-250 million shares would need to be covered at buyout or approval. The question becomes...where will these shares come from and at what price?
Source of that information?
I’ll show them some mercy. They can cover my shares for $20
This is great information and a reminder about duty to disclose. I remember a distinct “coincidence” between the JTM article release and ASCO. I would imagine that timelines can be somewhat manipulated by management.
Once the SAP is greenlit, you just apply it to the data. It’s actually very simple to apply the data. Probably an easy MS excel sheet calculation to unblind and get data results.
SO...if you knew that you’d have a final SAP by early May and all you had to do was apply it to the dataset, maybe it would make sense to wait until late May to apply it? Then walk into ASCO on June 2nd and announce?
SEC regulations say they have two weeks to announce the data after it is known, right?
Let’s assume that maybe these processes are being timed out by management. They did say “month’s long” processes at SNO. They know where we’re at with SAPs. They know how long data lock will take.
It’s amazing how JTM article came out just before ASCO last year. If we knew we’d get topline data in the next 4 weeks, would we just blurb it out on a random Tuesday or Thursday? Or perhaps find a good time/place to announce it?
Ahhh, the pump and dump theory. I’m not here for nickels ex. I’m more into money that folds.
What’s more important, timelines or data?
There’s plenty of money to get to the data. Once this treatment is validated, it’s game over. That could be June or September. The money won’t run out before then.
Maybe I’m wrong on timelines. Data will be the determining factor.
That’s a tried and true strategy in biotech. Late Sunday big breaking news. PR it on Monday and let the market absorb it upon open.
Only 27 market days left for shorts to instill fear and walk down the price here. June 3rd could be the end of the uncertainty.
I wouldn’t miss this presentation. If Dr. Liau comes in for the event, I’d be even more convinced that data will be presented.
I really want to panic and sell all my shares on the eve of topline data...
The price action just doesn’t create a ton of fear for me. I’ll wait to freak out for when they announce the trial failed.
I disagree. Anyone who is holding now isn’t selling before topline. Volume has dried up as everyone is in “wait and see” mindset. The only shares traded are those being printed by the market makers for the traders.
The big move will come after data is announced. The longer data is delayed, the more shares the “printers” may have to cover. Depending on how positive or negative data is, the swing could be substantial. Far more than a dollar or two. $20 might be a stretch, but $10 seems realistic with positive data that surprises the market.
The real winners could be the lucky ones who are buying now at these prices right before a potential massive upswing.
Phase 3 trials on personalized dendritic cell vaccines go back to 2008. It’s not new. Results will be new.
Not much. The charge per fraction goes up significantly for short course radiotherapy. This is done in recognition of the fact that most of the cost of radiotherapy is the equipment cost and planning/setup costs. So maybe 50k-60k cost for short course?
A course of radiotherapy is between $15k-$80k, depending on the number of fractions and complexity. For GBM, it’s probably closer to $80k for 30 fractions. I’ve heard that Temodar goes for around $2.5k per dose.
If you think the market knows anything, you’re sadly mistaken.
LP and the company have perfected silence. When Earth shaking news hits, it won’t be telegraphed. It will come as a complete surprise to the market.
The fact that Dr. Sharpless has a TBA topic for his talk tomorrow at a location that is quite meaningful for this trial, really intrigues me. The timing on this could be quite significant.
But, I could be wrong and back to “stay tuned” by Thursday.
I can confirm he made the same comparisons to me.
It takes a lot to impress you these days Flipper.
I’m hoping that the news and results we could see over the course of the next 3 months washes away the bitter taste of “stay tuned”.
I’d prefer that he wait until we have positive topline and and then PR the hell out of it. Let’s shock the market! That’s how large corrections happen.
Dave’s words to me were...I didn’t leave Oppenheimer to come here and watch NWBO go from .30 to $2. I came to watch it go to $20 and higher.
There is a reason it is illegal. If it was a fair market practice and could be tolerated, naked shorting should be legal.
Why do we have laws if they aren’t enforced? We get appalled by burglary when it happens in our businesses and homes, but our government permits it when it occurs in our trading accounts.
Your jokes are terrible alpha...SMH.
Fortunately, you do have other redeeming qualities.
Yup...$2 million fine? That was FINRAs commission in the deal for compliance.
When management says no mercy to the naked shorts, it’s really up to the shareholders to implement that. The more we make them chase $30-$100 in a panic or squeeze, the more likely that the price gets to that point.
It’s not only the “Wolfpack” that can collude on market prices.
My sell orders are all set as well. My mean sell point is about $30 as well.
This volume feels like trading has halted.
I’m hoping it’s the calm before the storm.
Maybe it’s the PGA Canyons course? I played there about 5 years ago. It has a beautiful view down over the Strip.
I spoke with Dave. Nice guy. Very positive. Exactly what you’d expect from a PR guy.
Most telling is his actions. Didn’t leave his job to come to NWBO to watch the company fail. He saw an amazing opportunity to get in at the ground level working for a company with huge potential.
Linda invested 5.4 million of her own money last April. Dave leaves Oppenheimer to get in on NWBO at this stage. Words on this board are worthless. Pay attention to the actions of company leadership.